Install
The Manila Times is a national daily newspaper in the Philippines that delivers trusted, quality content in print and digital editions.
- 86,844articles · 365d
- 2+ hour agolatest article
- Sep 13, 2025earliest in window
- 94%with images
- 266avg words
- business 35,564
- tmt newswire 25,298
- globenewswire 21,615
- technology 17,053
- markets 11,557
- stock 11,084
- artificial intelligence 10,650
- stocks 9,102
- ai 8,859
- companies 7,653
- finance 7,405
- politics 7,105
- world 6,333
- local news 6,325
- finanzen 6,307
- health 5,882
- lifestyle 5,751
- 2026 5,402
- business news 4,894
- sports 4,803
- Economy, Business & Finance 46,507
- Finance & Business 38,038
- News 30,507
- Business & Industrial 10,890
- Politics 7,756
- Finance 7,588
- Science & Technology 5,936
- Medical 5,570
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
2+ mon, 1+ week ago (129+ words) Q1: Is this announcement an efficacy readout? A1: No. This announcement reports a clinical operations milestone. Efficacy and safety data will be reported with topline results in Q4 2026. Q2: What patient populations could VLS-01 target? Q3: Why is AtaiBeckley targeting MDD with VLS-01 rather than…...
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
2+ mon, 3+ week ago (220+ words) Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies Microdosing refers to taking low, sub-perceptual doses of a psychedelic on a repeated schedule. Common regimens include the Fadiman protocol (one…...
Everbright Health Announces AI-Enabled Platform to Unlock Access to Advanced Mental Health Interventions
5+ mon, 6+ day ago (264+ words) The Manila Times New Platform Streamlines Path from Eligibility to Care for Patients Who Are Resistant to Standard Treatments SAN FRANCISCO, April 07, 2026 (GLOBE NEWSWIRE) -- Everbright Health, an AI-enabled services platform that helps mental health providers deliver advanced interventions as part…...
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
5+ mon, 2+ week ago (113+ words) "Publication in JAMA Psychiatry provides independent peer-reviewed validation of our Phase 2b findings,” said Dr. Velichka Valcheva, Chief Executive Officer. "This supports our ongoing efforts to advance GH001 into global pivotal trials.” New Finding: GH001 Efficacy Is Independent of Prior Treatment Failures A…...
NeuroSigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program
9+ mon, 3+ week ago (389+ words) Company dispensed over 1,000 FDA-cleared systems in pilot phase; unveils new website and second-generation device for early 2026 launch... NeuroSigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program Company dispensed over 1,000 FDA-cleared systems in pilot phase; unveils new website…...
Spark Biomedical Awarded an NIH Grant to Study the Treatment Effects of tAN® for Alcohol Withdrawal Symptoms
10+ mon, 3+ week ago (159+ words) STTR Phase I AUD study to be conducted in partnership with Menninger Clinic and Baylor College of Medicine Securing this NIH/NIAAA award amid today’s competitive funding environment is especially meaningful. Spark Biomedical is grateful for the unwavering dedication of…...
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
11+ mon, 2+ week ago (167+ words) Dosing and follow-up in the open-label extension (OLE) stage of the Phase 2b study, which is evaluating the effects of a 12 mg dose of BPL-003 administered eight weeks after the initial dose in the core study, is complete and data are…...